Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances


This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this issociative drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as PDF

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on methoxetamine: a summary
  • Risk Assessment Report of a new psychoactive substance: methoxetamine
  • Annex 1: Technical report on methoxetamine
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Additional downloads